全球卵巢癌诊断市场

预计到 2030 年全球卵巢癌诊断市场规模将达 58 亿美元

全球卵巢癌诊断市场规模预计在2024年为47亿美元，预计到2030年将达到58亿美元，在分析期内（2024-2030年）的复合年增长率为3.5%。上皮性肿瘤是本报告分析的细分市场之一，预计其复合年增长率为4.4%，到分析期结束时将达到23亿美元。生殖细胞肿瘤细分市场在分析期间的复合年增长率估计为2.5%。

美国市场规模估计为 13 亿美元，中国市场预期复合年增长率为 6.7%

美国卵巢癌诊断市场规模预计2024年达到13亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到12亿美元，在2024-2030年的分析期间内，复合年增长率为6.7%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为1.3%和2.8%。在欧洲，预计德国市场的复合年增长率为2.0%。

全球卵巢癌诊断市场—主要趋势与驱动因素摘要

卵巢癌诊断市场为何如此强劲？

由于卵巢癌发病率的上升以及早期发现需求的日益增长，卵巢癌诊断市场正在经历强劲增长。卵巢癌仍然是最致命的妇科恶性肿瘤之一，因为其早期无症状，及时诊断对于提高存活率至关重要。随着人们对卵巢癌筛检认识的不断提高，医疗保健提供者和研究人员正在投资先进的诊断工具，以便在早期、更易于治疗的阶段发现疾病。

此外，政府倡议、癌症宣传计划以及基于生物标誌物的检测的进步正在推动市场扩张。随着基因检测方法的改进和液态切片技术的日益普及，卵巢癌诊断变得更加准确、更容易获得且侵入性更小。

液态切片和主导筛检将如何改变卵巢癌诊断？

液态切片技术的发展正在彻底改变卵巢癌的诊断方式，因为它能够非侵入性地检测循环肿瘤DNA (ctDNA) 和RNA标记物。这些检测为传统切片检查提供了一种相当前景的替代方案，并能够即时监测癌症进展和治疗反应。

人工智慧诊断工具也透过分析影像扫描、基因数据和组织病理学样本来提高早期诊断率。机器学习演算法可以识别卵巢恶性肿瘤的模式，减少诊断错误，并加快临床决策速度。人工智慧与卵巢癌诊断的整合有望显着提高疾病检测的准确性和效率。

个人化医疗和基因检测是否会扩大市场机会？

个人化医疗的兴起正在改变卵巢癌的诊断，基因检测在识别高风险族群方面发挥关键作用。 BRCA1 和 BRCA2 突变检测以及多基因面板检测，正在协助制定有针对性的筛检和预防策略。

製药公司和诊断实验室越来越重视伴随诊断，这种诊断可根据个别基因图谱来指导治疗决策。精准医疗和标靶治疗的普及进一步推动了针对特定患者群体量身定制的先进诊断解决方案的需求。

推动卵巢癌诊断市场成长的因素是什么？

卵巢癌诊断市场的成长受到多种因素的推动，包括人们对早期检测的认识不断提高、液态切片和人工智慧筛检的进步，以及基因检测在个人化医疗中日益重要的作用。朝向非侵入性诊断技术的转变，使得卵巢癌检测更加便捷有效。

此外，政府对癌症研究的津贴不断增加、新型生物标记的开发以及对全民筛检计画的日益重视，都在推动市场成长。随着诊断技术的不断发展，卵巢癌检测有望变得更加准确和挽救生命。

部分

癌症类型（上皮肿瘤、生殖细胞肿瘤、基质细胞肿瘤和其他癌症类型）；诊断方法（影像、血液检查、切片检查和其他诊断方法）；最终用户（医院实验室、癌症诊断中心、研究和其他最终用户）

受访公司范例

• Abbott Laboratories
• Agilent Technologies
• Aspira Women's Health
• Becton, Dickinson and Company（BD）
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Foundation Medicine
• GE Healthcare
• GRAIL, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Merck KGaA
• Myriad Genetics, Inc.
• NanoString Technologies
• Oncocyte Corporation
• PerkinElmer Inc.
• Quest Diagnostics
• Roche Holding AG
• Siemens Healthineers
• Thermo Fisher Scientific

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 比赛

Global Ovarian Cancer Diagnostics Market to Reach US$5.8 Billion by 2030

The global market for Ovarian Cancer Diagnostics estimated at US$4.7 Billion in the year 2024, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Epithelial Tumor, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Germ Cell Tumor segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 6.7% CAGR

The Ovarian Cancer Diagnostics market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Ovarian Cancer Diagnostics Market - Key Trends & Drivers Summarized

Why Is the Ovarian Cancer Diagnostics Market Gaining Momentum?

The ovarian cancer diagnostics market is witnessing strong growth due to the rising prevalence of ovarian cancer and the increasing need for early detection. Ovarian cancer remains one of the most lethal gynecological malignancies due to its asymptomatic nature in early stages, making timely diagnosis critical for improving survival rates. As awareness of ovarian cancer screening grows, healthcare providers and researchers are investing in advanced diagnostic tools to detect the disease at an earlier and more treatable stage.

Additionally, government initiatives, cancer awareness programs, and advancements in biomarker-based testing are driving market expansion. With improved genetic testing methods and the increasing adoption of liquid biopsy techniques, ovarian cancer diagnostics are becoming more accurate, accessible, and less invasive.

How Are Liquid Biopsy and AI-Driven Screening Transforming Ovarian Cancer Diagnosis?

The development of liquid biopsy techniques is revolutionizing ovarian cancer diagnostics by enabling non-invasive detection through circulating tumor DNA (ctDNA) and RNA markers. These tests are offering a promising alternative to traditional biopsy procedures, allowing for real-time monitoring of cancer progression and treatment response.

AI-powered diagnostic tools are also improving early detection rates by analyzing imaging scans, genetic data, and histopathological samples. Machine learning algorithms can identify patterns indicative of ovarian malignancies, reducing diagnostic errors and enabling faster clinical decision-making. The integration of AI in ovarian cancer diagnostics is expected to significantly enhance accuracy and efficiency in disease detection.

Are Personalized Medicine and Genetic Testing Expanding Market Opportunities?

The rise of personalized medicine is reshaping ovarian cancer diagnostics, with genetic testing playing a crucial role in identifying individuals at high risk of developing the disease. BRCA1 and BRCA2 mutation testing, along with multi-gene panel testing, is allowing for targeted screening and preventive strategies.

Pharmaceutical companies and diagnostic labs are increasingly focusing on companion diagnostics that guide treatment decisions based on an individual’s genetic profile. The expansion of precision medicine and targeted therapies is further driving demand for advanced diagnostic solutions tailored to specific patient populations.

What’s Driving the Growth of the Ovarian Cancer Diagnostics Market?

The growth in the ovarian cancer diagnostics market is driven by several factors, including increasing awareness of early detection, advancements in liquid biopsy and AI-powered screening, and the expanding role of genetic testing in personalized medicine. The shift toward non-invasive diagnostic techniques is making ovarian cancer detection more accessible and effective.

Additionally, rising government funding for cancer research, the development of novel biomarkers, and the growing emphasis on population-wide screening programs are accelerating market growth. As diagnostic technologies continue to evolve, ovarian cancer detection is expected to become more precise and life-saving.

SCOPE OF STUDY:

The report analyzes the Ovarian Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor, Other Cancer Types); Diagnostic Method (Imaging, Blood Tests, Biopsy, Other Diagnostic Methods); End-Use (Hospital Laboratories End-Use, Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• Agilent Technologies
• Aspira Women's Health
• Becton, Dickinson and Company (BD)
• bioMerieux SA
• Bio-Rad Laboratories, Inc.
• Foundation Medicine
• GE Healthcare
• GRAIL, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Merck KGaA
• Myriad Genetics, Inc.
• NanoString Technologies
• Oncocyte Corporation
• PerkinElmer Inc.
• Quest Diagnostics
• Roche Holding AG
• Siemens Healthineers
• Thermo Fisher Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Ovarian Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence and Late Detection of Ovarian Cancer Throw the Spotlight on Early Diagnostic Solutions
  • Advancements in Liquid Biopsy and Biomarker Technology Accelerate Innovation in Diagnostics
  • Growing Awareness Campaigns and Routine Screening Programs Drive Adoption
  • Shift Toward Personalized Medicine Strengthens Business Case for Genomic Testing
  • High Mortality Rates Propel Demand for High-Sensitivity, Non-Invasive Detection Tools
  • Integration of AI in Image Analysis Supports Clinical Decision-Making in Diagnostics
  • Government Grants and Research Funding Sustain Innovation in Early Detection Platforms
  • Collaborations Between Pharma and Diagnostics Firms Accelerate Co-Development Strategies
  • Expansion of Direct-to-Consumer Genetic Testing Opens New Market Channels
  • Clinical Trial Expansion Fuels Demand for Companion Diagnostics in Oncology
  • Health System Digitization and Data Integration Improve Test Accessibility and Utility
  • Reimbursement Expansion for Advanced Diagnostics Drives Market Uptake
  • Growing Use of Multi-Cancer Early Detection Panels Enhances Ovarian Test Value
  • Diagnostic Labs and Startups Attract Investment for Point-of-Care Development
  • Regulatory Approvals of Novel Testing Kits Propel Market Entry in Developed and Emerging Markets
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Ovarian Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Ovarian Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Ovarian Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Epithelial Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Epithelial Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Epithelial Tumor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Germ Cell Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Germ Cell Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Germ Cell Tumor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Stromal Cell Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Stromal Cell Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Stromal Cell Tumor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Cancer Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Cancer Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Cancer Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospital Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospital Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Blood Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Blood Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Blood Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Diagnostic Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Diagnostic Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Diagnostic Methods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• JAPAN
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• CHINA
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• EUROPE
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Ovarian Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Ovarian Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• FRANCE
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• GERMANY
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Ovarian Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Ovarian Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• INDIA
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Ovarian Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Ovarian Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Ovarian Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Ovarian Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030
• AFRICA
  • Ovarian Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Ovarian Cancer Diagnostics by Cancer Type - Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Ovarian Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor and Other Cancer Types for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Ovarian Cancer Diagnostics by End-Use - Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Ovarian Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Cancer Diagnostic Centers End-Use, Research Institutes End-Use, Other End-Uses and Hospital Laboratories End-Use for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Ovarian Cancer Diagnostics by Diagnostic Method - Imaging, Blood Tests, Biopsy and Other Diagnostic Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Ovarian Cancer Diagnostics by Diagnostic Method - Percentage Breakdown of Value Sales for Imaging, Blood Tests, Biopsy and Other Diagnostic Methods for the Years 2015, 2025 & 2030

IV. COMPETITION